Introduction. The leading role of the human papillomavirus in the etiopathogenesis of malignant neoplasms of some localizations is generally recognized. Vaccines that are used in the world and in Russia for the prevention of papillomavirus infection create the basis for the elimination of diseases associated with the human papillomavirus in the future. The aim of the study is to determine the regional, gender and age-specific features of cancers associated with the human papillomavirus to substantiate the development of a unified system of epidemiological surveillance and vaccination. Materials and methods. The retrospective epidemiological analysis of the incidence of cancers associated with the human papillomavirus and mortality due to these neoplasms in the regions of the North-Western Federal District of Russia in 20112020 was carried out based on data from Statistic Form 7 "Information on malignant neoplasms" and the Population cancer Registers of St. Petersburg (13,117 cases), Leningrad region (3204 cases) and the Kaliningrad region (2898 cases). Results. In the structure of cancers associated with the human papillomavirus in St. Petersburg, Leningrad and Kaliningrad regions, more than 90% of men had tumors of the oral cavity, oropharynx and larynx, more than 60% of women had cervical cancer. Regional and age-specific features of the incidence of cervical cancer and mortality from this pathology have been established. Statistically significant differences in the incidence of cancer of the head and neck, anus and anal canal in different age groups of the male and female population were revealed. Conclusion. As a result of the study, regional, gender and age-specific features of the incidence of human papillomavirus-associated malignant neoplasms in the North-West of Russia were established. These data should be used to develop a system of epidemiological surveillance of papillomavirus infection and vaccination program.
Introduction: Combating the epidemic of the novel coronavirus disease required decision-making at the state level and joining efforts of medical workers of all specialties. The experience of the Kaliningrad Region deserves special attention since this region is located in Central Europe and the first COVID-19 cases were imported here in March 2020. Objective: To assess COVID-19 epidemic manifestations and effectiveness of preventive measures at the regional level. Materials and methods: We performed a retrospective epidemiological analysis of COVID-19 incidence in the Kaliningrad Region from March 2020 to December 2022. All registered cases were confirmed by PCR or immunochromatography assay. The study included 193,259 cases, 1,879 fatal cases, 1,168 samples with the established SARS-CoV-2 genetic variant, and information on 693,627 people vaccinated against COVID-19. The data were analyzed in Microsoft Excel and WinPepi (version 11.65). Results: In 2020, the COVID-19 incidence rate in the Kaliningrad Region was lower than that in the Russian Federation while in the years 2021 and 2022 the regional rates were, on the opposite, higher than the respective national ones (p < 0.05). All age groups of the population were involved in the outbreak. Periodic rises in the incidence were associated with the replacement of the Delta variant of SARS-CoV-2 with Omicron. We established high efficacy of vaccination against COVID-19: incidence and mortality rates among the unvaccinated were significantly higher than those among vaccinated individuals (p < 0.05). Conclusion: Organization of uniform infection control measures has enabled timely interdepartmental managerial decision-making to control the epidemic. Russian regions have accumulated unique experience in implementing a set of preventive and anti-epidemic measures to combat the epidemic of the novel infection.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.